27 July 2017 EMA/477146/2017 EMEA/H/C/001222

Public statement

Repso Withdrawal of the marketing authorisation in the European Union

On 19 July 2017, the European Commission withdrew the marketing authorisation for Repso (leflunomide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Repso was granted marketing authorisation in the EU on 14 March 2011 for the treatment of active rheumatoid and active psoriatic arthritis. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016. Repso is a generic medicine of Arava. There are other generic medicinal products of Arava authorised and marketed in the EU. The European Public Assessment Report (EPAR) for Repso will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

Withdrawal of the marketing authorisation in the European Union

Jul 27, 2017 - Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520. Send a question via our website www.ema.europa.eu/contact. © European ...

64KB Sizes 19 Downloads 249 Views

Recommend Documents

Withdrawal of the marketing authorisation in the European Union
Jul 27, 2017 - On 19 July 2017, the European Commission withdrew the marketing authorisation for Repso (leflunomide) in the European Union (EU).

Public statement on Enzepi: Withdrawal of the marketing authorisation ...
Jul 26, 2017 - On 19 July 2017, the European Commission withdrew the marketing authorisation for Enzepi (pancreas powder) in the European Union (EU).

the european union and the 'european dimension' in ...
Apr 18, 2008 - European Commission and Parliament to add a 'European dimension' ..... priorities figured the adoption of curricular themes that portrayed "the.

The-European-Union-And-Russia-The-European-Union-Series.pdf ...
institutional development of EU-Russia relations from three perspectives: European studies, Russian studies and International. Relations, including Foreign ...

EVDAS training for Marketing Authorisation Holders - European ...
Jan 1, 2017 - Understand the access to EudraVigilance provided via the EudraVigilance Data Analysis. System (EVDAS). • Be familiar with the EVDAS user ...

EUROPEAN UNION COUNTRIES IN THE PRESENT DAYS.pdf ...
Page 1 of 2. EUROPEAN UNION MEMBER COUNTRIES. Austria. EU member country since: 1 January 1995. Belgium. EU member state since: 1 January 1958.

Initial (Full) marketing authorisation application - European Medicines ...
C9. 06/09/2017. 07/09/2017. 21/09/2017. 27/09/2017. 02/10/2017. 06/10/2017. 12/10/2017. C10. 29/09/2017. 02/10/2017. 16/10/2017. 22/10/2017. 27/10/2017.

marketing authorisation application - European Medicines Agency
A1. 02/01/2017. 19/01/2017. 08/04/2017. 21/04/2017. 28/04/2017. 28/04/2017. 05/05/2017. 05/05/2017. 05/05/2017. 08/05/2017. 11/05/2017. 18/05/2017. A2.

EVDAS training for Marketing Authorisation Holders - European ...
Jan 1, 2017 - Revised definition and process for emerging safety issues, previously addressed in GVP. Module VI. • Streamlined information on scientific aspects of signal management. • Clarifications on terminology, roles and responsibilities and

EVDAS training for Marketing Authorisation Holders - European ...
Jan 1, 2017 - download (*EVPM). ICSR creation. ICSR ... The following illustration shows the report's filters. EV-M5b - EVDAS .... Grouping is a manual activity performed by the Agency to facilitate such analysis. ...... The ICSR is provided in PDF f

Marketing authorisation renewal application - European Medicines ...
The validation period between submission date and start date is usually sixteen calendar days. (**) Comments from PRAC and CHMP members are not made available to Marketing Authorisation Holders. (***) An updated AR is optional and dependent on the co

Marketing authorisation renewal application - ATMP - European ...
Reproduction is authorised provided the source is acknowledged. Page 1 / 7. EMA/825017/2015 Rev.1. Human Medicines Evaluation. The timetables in this document may be subject to revision. Marketing authorisation renewal application - ATMP. Assessment

The European Union
identity, a uniquely European sense of self and conception of the good life, has ... Email: [email protected] .... that nation states have appealed to but by subscription to democratic values and ...... European Parliament Press Service.

PDF The Economics of the European Union
pdf The Economics of the European Union: Policy and Analysis, The Economics of the European Union: Policy and. Analysis Free download, download The Economics of the European Union: Policy and Analysis, The Economics of the. European Union: Policy and

Introduction to the European Union regulatory system and European ...
Please send an email to EMA at [email protected] to register your ... Benefit/Risk Assessment and Good Regulatory Practices. Moderator: Jordi ...

First Written Submission by the European Union
The EU for its part had raised the issue of the export restraints as one of a number of ..... China is a leading global producer of all nine of these Raw Materials. ..... quota; (iii) the "business management capacity" of the applicant; and (iv) the.

Liability in cloud computing: the European Union Data ...
will research the effects of cloud computing on the EU directive and will suggest, if .... controllers, and cloud service providers who delegate to processors as ...

HABERMAS, Jürgen. The crisis of the European Union in the light of ...
dilemma, one which even the conservative Frankfurter Allgemeine Zeitung now para- phrases with the laconic formula 'More Europe'. All of the governments concerned. lack courage and are thrashing around helplessly in the dilemma between the impera- ti

Interest group success in the European Union
tions against unfair labor practices” (1995, p. 143). This suggests that while capitalist systems give considerable political leverage to business corporations, trade unions and citizen groups constitute “countervailing powers” (Galbraith, 1952